Quick Answer
Trevi Therapeutics, Inc. reported Operating Income of -$49.33 million for fiscal year 2025.
Trevi Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$49.33M | +4.3% |
| 2024 | -$51.52M | -51.9% |
| 2023 | -$33.92M | -13.4% |
| 2022 | -$29.91M | +7.9% |
| 2021 | -$32.48M | +0.0% |
| 2020 | -$32.49M | -21.9% |
| 2019 | -$26.64M | -44.7% |
| 2018 | -$18.41M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$13.92M | +1.2% | -1.4% |
| June 30, 2025 | -$13.72M | -3.3% | -19.6% |
| March 31, 2025 | -$11.47M | +3.7% | +18.6% |
| September 30, 2024 | -$14.09M | -55.7% | -6.0% |
| June 30, 2024 | -$13.29M | -58.5% | -11.6% |
| March 31, 2024 | -$11.91M | -57.4% | -31.6% |
| September 30, 2023 | -$9.04M | -7.6% | -7.9% |
| June 30, 2023 | -$8.38M | -7.2% | -10.8% |
- Trevi Therapeutics, Inc. showed an increase of +4.3% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Trevi Therapeutics, Inc.’s operating income has declined by 168.0% (from -$18.41 million to -$49.33 million).
- The most recent figure is from Trevi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: